Josep Lluis Carbonell Esteve
Research Subjects
Josep Lluis Carbonell Esteve has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
C Sánchez
Hospital Docente Gineco-Obstétrico “Eusebio Hernández” (Maternidad Obrera), Havana, Cuba
2 shared publicationsCarlos Sanchez
Eusebio Hernandez Gynecology and Obstetrics Teaching Hospital, Havana, Cuba
2 shared publicationsF Valero
Clínica Delta Medica, Murcia, Spain
2 shared publicationsGiuseppe Tomasi
University of the Basque Country, Bilbao, Spain
2 shared publicationsI Salvador
Clínica “Mediterrania Medica,” C/ Salvador Guinot 14, Valencia 46017, Spain
2 shared publicationsJ Marí
Clínica “Mediterrania Medica,” C/ Salvador Guinot 14, Valencia 46017, Spain
2 shared publications
Latest Publications
- Open Access
- 1 January 2015
- Published by Taylor & Francis in International Journal of Women's Health
- Vol. 7, 95-102
Mifepristone 5 mg versus 10 mg for emergency contraception: double-blind randomized clinical trial
Purpose: To estimate the efficacy and safety of 5 mg and 10 mg mifepristone for emergency contraception up to 144 hours after unprotected coitus. Methods: This double-blind randomized clinical trial was carried out at Eusebio Hernandez Hospital (Havana, Cuba). A total of 2,418 women who requested emergency contraception after unprotected coitus received either 5 mg or 10 mg mifepristone. The variables for assessing efficacy were the pregnancies that occurred and the fraction of pregnancies that were prevented. Other variables assessed were the side effects of mifepristone, vaginal bleeding, and changes in the date of the following menstruation. Results: There were 15/1,206 (1.2%) and 9/1,212 (0.7%) pregnancies in the 5 mg and 10 mg group, respectively (P=0.107). There were 88% and 93% prevented pregnancies in the 5 mg and 10 mg group, respectively. The side effect profiles were similar in both groups. Delayed menstruation ≥7 days was experienced by 4.9% and 11.0% of subjects in the 5 mg and 10 mg group, respectively (P=0.001). There was a significant high failure rate for women weighing >75 kg in the 5 mg group. Conclusion: It would be advisable to use the 10 mg dose of mifepristone for emergency contraception as there was a trend suggesting that the failure rate of the larger dose was lower.
- 1 January 2015
- Published by Taylor & Francis in International Journal of Women's Health
- Vol. 7, 95-102
Open AccessMifepristone 5 mg versus 10 mg for emergency contraception: double-blind randomized clinical trial
Purpose: To estimate the efficacy and safety of 5 mg and 10 mg mifepristone for emergency contraception up to 144 hours after unprotected coitus. Methods: This double-blind randomized clinical trial was carried out at Eusebio Hernandez Hospital (Havana, Cuba). A total of 2,418 women who requested emergency contraception after unprotected coitus received either 5 mg or 10 mg mifepristone. The variables for assessing efficacy were the pregnancies that occurred and the fraction of pregnancies that were prevented. Other variables assessed were the side effects of mifepristone, vaginal bleeding, and changes in the date of the following menstruation. Results: There were 15/1,206 (1.2%) and 9/1,212 (0.7%) pregnancies in the 5 mg and 10 mg group, respectively (P=0.107). There were 88% and 93% prevented pregnancies in the 5 mg and 10 mg group, respectively. The side effect profiles were similar in both groups. Delayed menstruation ≥7 days was experienced by 4.9% and 11.0% of subjects in the 5 mg and 10 mg group, respectively (P=0.001). There was a significant high failure rate for women weighing >75 kg in the 5 mg group. Conclusion: It would be advisable to use the 10 mg dose of mifepristone for emergency contraception as there was a trend suggesting that the failure rate of the larger dose was lower.
- Open Access
- 1 June 2013
- Published by Taylor & Francis in International Journal of Women's Health
- Vol. 5, 361-369
Mifepristone versus placebo to treat uterine myoma: a double-blind, randomized clinical trial
Objective: To evaluate the efficacy, safety, and quality of life of 5 mg mifepristone per day compared with a placebo in treating uterine fibroids. Design: Randomized, double-blind clinical study. Location: Eusebio Hernández Gynecology and Obstetrics Teaching Hospital, Havana, Cuba. Subjects: One hundred twenty-four subjects with symptomatic uterine fibroids. Treatment: One daily capsule of 5 mg mifepristone or a mifepristone placebo over 3 months. Variables in evaluating safety: Changes in fibroid and uterine volumes, changes in symptom prevalence and intensity, and changes in quality of life. Results: Three months into treatment, fibroid volume was reduced by 28.5% in the mifepristone group with an increase of 1.8% in the placebo group (P = 0.031). There were significant differences between the groups with respect to pelvic pain prevalence (P = 0.006), pelvic pressure (P = 0.027), rectal pain (P = 0.013), hypermenorrhea (P < 0.001), and metrorrhagia (P = 0.002) at the end of treatment. Amenorrhea was 93.1% and 4.3% in the mifepristone and placebo groups, respectively (P < 0.001). Treatment side effects were significantly greater in the mifepristone group. Estradiol levels did not differ significantly between the placebo and mifepristone groups at the end of treatment. Improvement in quality of life was significantly greater in the categories of "symptoms" (P = 0.004) and "activity" (P = 0.045) in the mifepristone group. Conclusion: The 5 mg dosage of mifepristone presented significantly superior efficacy compared to the placebo.
- 1 June 2013
- Published by Taylor & Francis in International Journal of Women's Health
- Vol. 5, 361-369
Open AccessMifepristone versus placebo to treat uterine myoma: a double-blind, randomized clinical trial
Objective: To evaluate the efficacy, safety, and quality of life of 5 mg mifepristone per day compared with a placebo in treating uterine fibroids. Design: Randomized, double-blind clinical study. Location: Eusebio Hernández Gynecology and Obstetrics Teaching Hospital, Havana, Cuba. Subjects: One hundred twenty-four subjects with symptomatic uterine fibroids. Treatment: One daily capsule of 5 mg mifepristone or a mifepristone placebo over 3 months. Variables in evaluating safety: Changes in fibroid and uterine volumes, changes in symptom prevalence and intensity, and changes in quality of life. Results: Three months into treatment, fibroid volume was reduced by 28.5% in the mifepristone group with an increase of 1.8% in the placebo group (P = 0.031). There were significant differences between the groups with respect to pelvic pain prevalence (P = 0.006), pelvic pressure (P = 0.027), rectal pain (P = 0.013), hypermenorrhea (P < 0.001), and metrorrhagia (P = 0.002) at the end of treatment. Amenorrhea was 93.1% and 4.3% in the mifepristone and placebo groups, respectively (P < 0.001). Treatment side effects were significantly greater in the mifepristone group. Estradiol levels did not differ significantly between the placebo and mifepristone groups at the end of treatment. Improvement in quality of life was significantly greater in the categories of "symptoms" (P = 0.004) and "activity" (P = 0.045) in the mifepristone group. Conclusion: The 5 mg dosage of mifepristone presented significantly superior efficacy compared to the placebo.
- Open Access
- 1 March 2012
- Published by Taylor & Francis in International Journal of Women's Health
- Vol. 4, 75-84
Mifepristone 2.5 mg versus 5 mg daily in the treatment of leiomyoma before surgery
Objectives: To evaluate the efficacy and safety of 2.5 mg and 5 mg mifepristone during 3 months for the treatment of uterine fibroids before surgery. Design: Multicenter randomized clinical trial. Locations: Eusebio Hernández Hospital, Havana, Cuba and the Alemán Hospital, Managua, Nicaragua. Subjects: Included in the study were 146 women with symptomatic uterine fibroids. Treatment: Group I: half a tablet of 5 mg (2.5 mg) mifepristone taken orally every 24 hours, and Group II: one tablet of 5 mg mifepristone taken orally every 24 hours over a period of 3 months in both groups. Two endometrial biopsies were performed. Variables to evaluate efficacy: Increase in average hemoglobin, changes in fibroid and uterine volume, and symptomatic improvement. Results: The average hemoglobin at the end of treatment was 0.6 g/dL greater in the 5 mg mifepristone group (P = 0.033). In both groups there were similar reductions in fibroid volumes. Clinical improvement was more significant in the 5 mg group. Conclusion: The dose to be used should be 5 mg.
- 1 March 2012
- Published by Taylor & Francis in International Journal of Women's Health
- Vol. 4, 75-84
Open AccessMifepristone 2.5 mg versus 5 mg daily in the treatment of leiomyoma before surgery
Objectives: To evaluate the efficacy and safety of 2.5 mg and 5 mg mifepristone during 3 months for the treatment of uterine fibroids before surgery. Design: Multicenter randomized clinical trial. Locations: Eusebio Hernández Hospital, Havana, Cuba and the Alemán Hospital, Managua, Nicaragua. Subjects: Included in the study were 146 women with symptomatic uterine fibroids. Treatment: Group I: half a tablet of 5 mg (2.5 mg) mifepristone taken orally every 24 hours, and Group II: one tablet of 5 mg mifepristone taken orally every 24 hours over a period of 3 months in both groups. Two endometrial biopsies were performed. Variables to evaluate efficacy: Increase in average hemoglobin, changes in fibroid and uterine volume, and symptomatic improvement. Results: The average hemoglobin at the end of treatment was 0.6 g/dL greater in the 5 mg mifepristone group (P = 0.033). In both groups there were similar reductions in fibroid volumes. Clinical improvement was more significant in the 5 mg group. Conclusion: The dose to be used should be 5 mg.
- 1 November 2008
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 112 (5) , 1029-1036
Mifepristone for the Treatment of Uterine Leiomyomas
To estimate the efficacy of daily administration of 5 mg compared with 10 mg of mifepristone for the treatment of uterine myomas. One hundred women were randomly assigned to receive oral mifepristone 5 mg or 10 mg daily for 3 months (50 per group). Abdominal ultrasonography was performed before treatment, at 45 days, and at 3 months to evaluate leiomyoma and uterine volumes. Endometrial biopsy specimens were taken before and after treatment. Efficacy was estimated by the reduction percentages of the leiomyoma and uterine volumes. After 90 days treatment there was a 45% (95% confidence interval [CI] 37-54, P<.001) and a 57% (95% CI 48-67, P<.001) reduction in the leiomyoma volume in the 10-mg and 5-mg groups, respectively, and one of 40% (95% CI 34-46, P=.002), and 36% (95% CI 31-40, P<.001), respectively, in the uterine volume. Symptomatic improvement was noted, and the prevalence of symptoms diminished significantly. There were no significant differences in reduction of volume and symptoms in the treatment groups, P>.05 in all cases. After treatment, 44 of 49 (89.8%) women from the mifepristone 10 mg group and 45 of 50 (90.0%) from the 5-mg group, respectively, were amenorrheic (P=.487). Endometrial biopsy after treatment showed simple hyperplasia in 1 of 50 (2.0%) in the mifepristone 10 mg group. Five-milligram doses of mifepristone produce reductions in leiomyoma and uterine volumes and symptomatic improvement similar to 10-mg doses. I.
- 1 November 2008
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 112 (5) , 1029-1036
Mifepristone for the Treatment of Uterine Leiomyomas
To estimate the efficacy of daily administration of 5 mg compared with 10 mg of mifepristone for the treatment of uterine myomas. One hundred women were randomly assigned to receive oral mifepristone 5 mg or 10 mg daily for 3 months (50 per group). Abdominal ultrasonography was performed before treatment, at 45 days, and at 3 months to evaluate leiomyoma and uterine volumes. Endometrial biopsy specimens were taken before and after treatment. Efficacy was estimated by the reduction percentages of the leiomyoma and uterine volumes. After 90 days treatment there was a 45% (95% confidence interval [CI] 37-54, P<.001) and a 57% (95% CI 48-67, P<.001) reduction in the leiomyoma volume in the 10-mg and 5-mg groups, respectively, and one of 40% (95% CI 34-46, P=.002), and 36% (95% CI 31-40, P<.001), respectively, in the uterine volume. Symptomatic improvement was noted, and the prevalence of symptoms diminished significantly. There were no significant differences in reduction of volume and symptoms in the treatment groups, P>.05 in all cases. After treatment, 44 of 49 (89.8%) women from the mifepristone 10 mg group and 45 of 50 (90.0%) from the 5-mg group, respectively, were amenorrheic (P=.487). Endometrial biopsy after treatment showed simple hyperplasia in 1 of 50 (2.0%) in the mifepristone 10 mg group. Five-milligram doses of mifepristone produce reductions in leiomyoma and uterine volumes and symptomatic improvement similar to 10-mg doses. I.
- 1 January 2007
- Published by Taylor & Francis in The European Journal of Contraception & Reproductive Health Care
- Vol. 12 (2) , 162-167
Emergency contraception in Cuba with 10 mg of mifepristone
Background Mifepristone in a dose of 10 mg is an effective emergency contraceptive when administered up to 120 hours after unprotected coitus. Methods Between May 2003 and February 2005, we conducted in Cuba a single-arm trial to evaluate the effectiveness of 10 mg mifepristone for emergency contraception up to 6 days after unprotected coitus. A total of 635 women who requested emergency contraception after a single act of unprotected intercourse were included in the study. Results After treatment there were 7/635 (1.1%) pregnancies (95% CI 0.4–2.3%). Pregnancy that might have occurred was prevented in 88.0% of the cases (95% CI 77.1–95.1%). The most common side effects reported by participants were fatigue (10.7%), dizziness (6.1%) and nausea (4.9%); vomiting was only reported by 0.6%. In 38/635 (6.0%) women menstruation was delayed more than 7 days. Conclusions Mifepristone 10 mg administered is an effective emergency contraceptive with an acceptable profile of side effects up to five days, but greater studies are necessary to verify its efficacy up to 6 days after unprotected intercourse.
- 1 January 2007
- Published by Taylor & Francis in The European Journal of Contraception & Reproductive Health Care
- Vol. 12 (2) , 162-167
Emergency contraception in Cuba with 10 mg of mifepristone
Background Mifepristone in a dose of 10 mg is an effective emergency contraceptive when administered up to 120 hours after unprotected coitus. Methods Between May 2003 and February 2005, we conducted in Cuba a single-arm trial to evaluate the effectiveness of 10 mg mifepristone for emergency contraception up to 6 days after unprotected coitus. A total of 635 women who requested emergency contraception after a single act of unprotected intercourse were included in the study. Results After treatment there were 7/635 (1.1%) pregnancies (95% CI 0.4–2.3%). Pregnancy that might have occurred was prevented in 88.0% of the cases (95% CI 77.1–95.1%). The most common side effects reported by participants were fatigue (10.7%), dizziness (6.1%) and nausea (4.9%); vomiting was only reported by 0.6%. In 38/635 (6.0%) women menstruation was delayed more than 7 days. Conclusions Mifepristone 10 mg administered is an effective emergency contraceptive with an acceptable profile of side effects up to five days, but greater studies are necessary to verify its efficacy up to 6 days after unprotected intercourse.
- 31 October 2006
- Published by Elsevier in Contraception
- Vol. 74 (4) , 328-333
Sublingual versus vaginal misoprostol (400 μg) for cervical priming in first-trimester abortion: a randomized trial
- 31 October 2006
- Published by Elsevier in Contraception
- Vol. 74 (4) , 328-333
Sublingual versus vaginal misoprostol (400 μg) for cervical priming in first-trimester abortion: a randomized trial
- 31 July 2004
- Published by Elsevier in Contraception
- Vol. 70 (1) , 55-60
Vaginal misoprostol 800 μg every 12 h for second-trimester abortion
- 31 July 2004
- Published by Elsevier in Contraception
- Vol. 70 (1) , 55-60
Vaginal misoprostol 800 μg every 12 h for second-trimester abortion
- 1 June 2003
- Published by Elsevier in Contraception
- Vol. 67 (6) , 457-462
Oral and vaginal misoprostol 800 μg every 8 h for early abortion
- 1 June 2003
- Published by Elsevier in Contraception
- Vol. 67 (6) , 457-462
Oral and vaginal misoprostol 800 μg every 8 h for early abortion